BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Giraudeau C, Leporq B, Doblas S, Lagadec M, Pastor CM, Daire JL, Van Beers BE. Gadoxetate-enhanced MR imaging and compartmental modelling to assess hepatocyte bidirectional transport function in rats with advanced liver fibrosis. Eur Radiol 2017;27:1804-11. [PMID: 27553933 DOI: 10.1007/s00330-016-4536-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Yang L, Ding Y, Rao S, Chen C, Zeng M. T1 Mapping on Gd-EOB-DTPA-Enhanced MRI for the Prediction of Oxaliplatin-Induced Liver Injury in a Mouse Model. J Magn Reson Imaging 2021;53:896-902. [PMID: 32979019 DOI: 10.1002/jmri.27377] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Noda Y, Goshima S, Okuaki T, Akamine Y, Kajita K, Kawai N, Kawada H, Tanahashi Y, Matsuo M. Hepatocyte fraction: correlation with noninvasive liver functional biomarkers. Abdom Radiol (NY) 2020;45:83-9. [PMID: 31552466 DOI: 10.1007/s00261-019-02238-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
3 Ziemian S, Green C, Sourbron S, Jost G, Schütz G, Hines CDG. Ex vivo gadoxetate relaxivities in rat liver tissue and blood at five magnetic field strengths from 1.41 to 7 T. NMR Biomed 2021;34:e4401. [PMID: 32851735 DOI: 10.1002/nbm.4401] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Im WH, Song JS, Jang W. Noninvasive staging of liver fibrosis: review of current quantitative CT and MRI-based techniques. Abdom Radiol (NY) 2021. [PMID: 34228199 DOI: 10.1007/s00261-021-03181-x] [Reference Citation Analysis]
5 Guo Y, Chu X, Parrott NJ, Brouwer KLR, Hsu V, Nagar S, Matsson P, Sharma P, Snoeys J, Sugiyama Y, Tatosian D, Unadkat JD, Huang SM, Galetin A; International Transporter Consortium. Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches. Clin Pharmacol Ther 2018;104:865-89. [PMID: 30059145 DOI: 10.1002/cpt.1183] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 15.5] [Reference Citation Analysis]
6 Akai H, Yasaka K, Kunimatsu A, Nojima M, Inoue Y, Abe O, Ohtomo K, Kiryu S. The inhibitory effect of gadoxetate disodium on hepatic transporters: a study using indocyanine green. Eur Radiol 2018;28:4128-33. [PMID: 29651770 DOI: 10.1007/s00330-018-5403-5] [Reference Citation Analysis]
7 Chen D, Zhao X, Xu H, Ren H, Liu T, Wang Y, Yang D, Yang Z. Noninvasive Assessment of APAP (N-acetyl-p-aminophenol)-Induced Hepatotoxicity Using Multiple MRI Parameters in an Experimental Rat Model. J Magn Reson Imaging 2022. [PMID: 35420237 DOI: 10.1002/jmri.28203] [Reference Citation Analysis]
8 Shuboni-Mulligan DD, Parys M, Blanco-Fernandez B, Mallett CL, Schnegelberger R, Takada M, Chakravarty S, Hagenbuch B, Shapiro EM. Dynamic Contrast-Enhanced MRI of OATP Dysfunction in Diabetes. Diabetes 2019;68:271-80. [PMID: 30487262 DOI: 10.2337/db18-0525] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Scotcher D, Melillo N, Tadimalla S, Darwich AS, Ziemian S, Ogungbenro K, Schütz G, Sourbron S, Galetin A. Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Disposition of Imaging Biomarker Gadoxetate in Rats. Mol Pharm 2021;18:2997-3009. [PMID: 34283621 DOI: 10.1021/acs.molpharmaceut.1c00206] [Reference Citation Analysis]
10 Weiss M, Siegmund W. Unusual Distribution Kinetics of Gadoxetate in Healthy Human Subjects Genotyped for OATP1B1: Application of Population Analysis and a Minimal Physiological-Based Pharmacokinetic Model. J Clin Pharmacol 2021;61:506-14. [PMID: 33084108 DOI: 10.1002/jcph.1762] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Leporq B, Daire JL, Pastor CM, Deltenre P, Sempoux C, Schmidt S, Van Beers BE. Quantification of hepatic perfusion and hepatocyte function with dynamic gadoxetic acid-enhanced MRI in patients with chronic liver disease. Clin Sci (Lond) 2018;132:813-24. [PMID: 29440620 DOI: 10.1042/CS20171131] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
12 Huh J, Ham SJ, Cho YC, Park B, Kim B, Woo CW, Choi Y, Woo DC, Kim KW. Gadoxetate-enhanced dynamic contrast-enhanced MRI for evaluation of liver function and liver fibrosis in preclinical trials. BMC Med Imaging 2019;19:89. [PMID: 31729971 DOI: 10.1186/s12880-019-0378-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Matoori S, Froehlich JM, Breitenstein S, Pozdniakova V, Reischauer C, Kolokythas O, Koh D, Gutzeit A. Serum albumin, total bilirubin, and patient age are independent confounders of hepatobiliary-phase gadoxetate parenchymal liver enhancement. Eur Radiol 2019;29:5813-22. [DOI: 10.1007/s00330-019-06179-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
14 Karageorgis A, Lenhard SC, Yerby B, Forsgren MF, Liachenko S, Johansson E, Pilling MA, Peterson RA, Yang X, Williams DP, Ungersma SE, Morgan RE, Brouwer KLR, Jucker BM, Hockings PD. A multi-center preclinical study of gadoxetate DCE-MRI in rats as a biomarker of drug induced inhibition of liver transporter function. PLoS One 2018;13:e0197213. [PMID: 29771932 DOI: 10.1371/journal.pone.0197213] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
15 Ronot M, Leporq B, Van Beers BE, Vilgrain V. CT and MR perfusion techniques to assess diffuse liver disease. Abdom Radiol (NY) 2020;45:3496-506. [PMID: 31768595 DOI: 10.1007/s00261-019-02338-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
16 Georgiou L, Penny J, Nicholls G, Woodhouse N, Blé FX, Naish JH, Hubbard Cristinacce PL. Modeling Gadoxetate Liver Uptake and Efflux Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging Enables Preclinical Quantification of Transporter Drug-Drug Interactions. Invest Radiol 2018;53:563-70. [PMID: 29771727 DOI: 10.1097/RLI.0000000000000480] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]